Good Therapeutics raises $11M to build algorithm-designed, locally-activating protein cancer therapies
Good Therapeutics, a Seattle biotech headed by founder and CEO John Mulligan, raised $11 million to develop an algorithm-designed protein platform that activates drugs only where and when needed to reduce systemic toxicity.